Neuropace Inc
NASDAQ:NPCE

Watchlist Manager
Neuropace Inc Logo
Neuropace Inc
NASDAQ:NPCE
Watchlist
Price: 10.2 USD -4.32% Market Closed
Market Cap: 297.8m USD
Have any thoughts about
Neuropace Inc?
Write Note

Neuropace Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Neuropace Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Neuropace Inc
NASDAQ:NPCE
Long-Term Debt
$57m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Long-Term Debt
$17.9B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
17%
Boston Scientific Corp
NYSE:BSX
Long-Term Debt
$9.2B
CAGR 3-Years
2%
CAGR 5-Years
-1%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Long-Term Debt
$13.3B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
15%
Abbott Laboratories
NYSE:ABT
Long-Term Debt
$13.1B
CAGR 3-Years
-9%
CAGR 5-Years
-6%
CAGR 10-Years
13%
Intuitive Surgical Inc
NASDAQ:ISRG
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Neuropace Inc
Glance View

Market Cap
303.7m USD
Industry
Health Care

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.

NPCE Intrinsic Value
9.6 USD
Overvaluation 6%
Intrinsic Value
Price

See Also

What is Neuropace Inc's Long-Term Debt?
Long-Term Debt
57m USD

Based on the financial report for Dec 31, 2023, Neuropace Inc's Long-Term Debt amounts to 57m USD.

What is Neuropace Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
4%

Over the last year, the Long-Term Debt growth was 8%. The average annual Long-Term Debt growth rates for Neuropace Inc have been 4% over the past three years .

Back to Top